A pilot feasibility and safety study of autologous umbilical cord blood cell therapy in infants with neonatal encephalopathy - Autologous cord blood cell therapy for neonatal encephalopathy

eonatal Encephalopathy Consortium, Japan0 sites6 target enrollmentAugust 26, 2014

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: eonatal encephalopathy (Neonatal hypoxic-ischemic encephalopathy)
Sponsor: eonatal Encephalopathy Consortium, Japan
Enrollment: 6
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

August 26, 2014

End Date

July 26, 2019

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

eonatal Encephalopathy Consortium, Japan

•1\) Known major congenital anomalies, such as chromosomal anomalies, heart diseases 2\) Major intracranial hemorrhage identified by brain ultrasonography or computed tomography 3\) Severe growth restriction, with birth\-weight less than 1800 g 4\) Severe infectious disease, such as sepsis 5\) Hyperkalemia 6\) Outborn infants (Infants born at hospitals other than the study sites) 7\) Volume of collected cord blood \<40 ml 8\) Infants judged critically ill and unlikely to benefit from neonatal intensive care by the attending neonatologist